Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?

This publication has 33 references indexed in Scilit:

• Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
  Blood, 2002
• Clinical Development of P glycoprotein Modulators in Oncology
  Published by Wiley ,2002
• The challenge of acute myeloid leukemia in older patients
  Current Opinion in Oncology, 2002
• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
  Blood, 2001
• Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial
  British Journal of Haematology, 2001
• Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial
  Bone Marrow Transplantation, 1999
• MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia
  British Journal of Haematology, 1997
• Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)
  Leukemia Research, 1996
• Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
  New England Journal of Medicine, 1995
• Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
  New England Journal of Medicine, 1994